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During 1997–2004, microbiologically conﬁ  rmed  gas-
trointestinal infections were reported for 101,855 patients 
in Sweden. Among patients who had Salmonella infection 
(n = 34,664), we found an increased risk for aortic aneurysm 
(standardized incidence ratio [SIR] 6.4, 95% conﬁ  dence in-
terval [CI] 3.1–11.8) within 3 months after infection and an 
elevated risk for ulcerative colitis (SIR 3.2, 95% CI 2.2–4.6) 
within 1 year after infection. We also found this elevated 
risk for ulcerative colitis among Campylobacter infections 
(n = 57,425; SIR 2.8, 95% CI 2.0–3.8). Within 1 year, we 
found an increased risk for reactive arthritis among patients 
with Yersinia enteritis (n = 5,133; SIR 47.0, 95% CI 21.5–
89.2), Salmonella infection (SIR 18.2, 95% CI 12.0–26.5), 
and Campylobacter infection (SIR 6.3, 95% CI 3.5–10.4). 
Acute gastroenteritis is sometimes associated with disease 
manifestations from several organ systems that may require 
hospitalization of patients. 
B
acterial gastrointestinal infections continue to cause 
illness and death and contribute to economic loss in 
most parts of the world, including high-income countries 
that have developed surveillance and control programs. The 
symptoms of acute bacterial intestinal infection are usually 
mild to moderate, and spontaneous remission occurs (1), 
but in some cases, the disease can cause rapid deterioration 
of a patient’s condition.
An episode of acute enteric infection involving ex-
traintestinal organs can also lead to complications and trig-
ger chronic disease. Complications include irritable bowel 
syndrome (2), reactive arthritis (3), hemolytic uremic syn-
drome (HUS) (4), and Guillain-Barré syndrome (GBS) (5). 
There may be other, perhaps unusual and less documented, 
late effects of acute enteric infections, such as inﬂ  amma-
tory bowel disease (6). 
In Sweden, there is no active follow-up on reported 
cases of bacterial enteric infection in terms of disease out-
come or long-term complications. During the 8-year period 
1997–2004, >100,000 persons with acute gastrointestinal 
infection were reported within the national surveillance 
program for communicable diseases. We present a retro-
spective cohort study of these patients to investigate the as-
sociation between exposure to a bacterial pathogen and the 
risk for autoimmune illness, gastrointestinal complications, 
and extraintestinal infectious disease. 
Materials and Methods 
Participants comprised persons with intestinal infec-
tion (nontyphoidal Salmonella spp., Campylobacter spp., 
Yersinia enterocolitica,  Shigella spp., or enterohemor-
rhagic Escherichia coli [EHEC]) reported to the Swedish 
Institute for Infectious Disease Control during 1997–2004. 
We collected data on age, sex, date reported, and country 
of infection and used social security numbers for identi-
ﬁ  cation. This identiﬁ  cation number was used to link our 
cohort of cases (those with short-term complications oc-
curring within 3 months or long-term effects within 1 year 
after infection) to the Swedish Hospital Discharge (covers 
all hospital in Sweden) and Causes of Death registers. Eth-
ics permission was obtained from the Ethical Committee, 
Karolinska Institute. Discharge diagnoses must be reported 
to the register; therefore, any study using this register is, in 
practice, population based. The Hospital Discharge Regis-
ter was validated by using a diagnosis of acute myocardial 
infarction; underreporting was <1%, main diagnosis was 
missing for <1% of cases, and correct diagnosis was made 
for 86% (7). 
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son-time from reported date of infection to an event, death, 
or study termination. Person-years were then compared 
with a Swedish standard population of 5-year age groups 
to calculate the expected number of cases for each disease. 
Standardized incidence ratios (SIRs) were constructed by 
dividing the observed number of cases with the expected 
number of cases. Ninety-ﬁ  ve percent exact conﬁ  dence in-
tervals (CIs) were calculated under the assumption that the 
number of observed cases were Poisson distributed. CIs that 
do not overlap 1 indicate that the number of observed cases 
is signiﬁ  cantly different from the number of cases expected 
in a population cohort of similar age and sex distribution. 
The described method is called indirect standardization, 
and interpretation of results is similar to relative risk inter-
pretation, i.e., comparing the risk for disease in an exposed 
cohort to the risk for disease in an unexposed cohort. 
We previously estimated standardized mortality ra-
tios (SMRs) for Salmonella (8) and Campylobacter infec-
tions (9) and showed that country of infection (domestic or 
abroad) was an effect modiﬁ  er; i.e., the SMR differed sub-
stantially between these 2 strata and no pooled SMR could 
be calculated. The underlying factor for this interaction was 
probably that the term abroad served as a proxy for healthi-
ness or a healthy traveler effect. For our present analysis, 
we divided the cohort into 2 strata on the basis of country of 
infection (Sweden or abroad), but no statistical signiﬁ  cant 
interaction was evident. We concluded that crude SIRs ir-
respective of country of infection could be estimated. All 
analyses were conducted by using SAS statistical software, 
version 8.2 (SAS Institute, Inc., Cary, NC, USA).
Results
Demographic data on the 101,855 study participants 
and frequency counts for infectious agents are summarized 
in Table 1. Campylobacter spp. caused the most cases, 
57,425 (56%). The second most frequent pathogen was 
Salmonella spp., the causative agent in 34,664 cases (34%); 
distribution of serovars is shown in Table 2. Of all cases 
of gastroenteritis, Yersinia spp. accounted for 5,133 (5%) 
cases; Shigella spp. 3,813 (4%); and EHEC 820 (<1%).
Table 3 shows the number of reported case-patients 
with speciﬁ  c diseases within 3 months of an episode of bac-
terial gastrointestinal infection, along with expected num-
ber of cases and SIRs. Not surprisingly, the highest risks 
were found for HUS after EHEC infection and GBS fol-
lowing campylobacter infection. Although SIRs were quite 
elevated, absolute risks were more moderate; among 820 
cases of EHEC infection, we found 13 episodes of HUS 
(1.6%), 57,425 cases of campylobacteriosis, 13 cases of 
GBS (0.02%), 5,133 cases of Yersinia infection, and 9 cas-
es of reactive arthritis (0.2%). The risk for aortic aneurysm 
among patients with salmonellosis was signiﬁ  cantly higher 
than expected (SIR 6.4, 95% CI 3.1–11.8). The absolute 
risk for bacteremia/sepsis was 0.02% for case-patients with 
Campylobacter infection and 0.03% for those with sal-
monellosis. For many complications, we did not ﬁ  nd any 
statistically signiﬁ  cant elevated risks. Other complications 
that we had hypothesized to be associated with gastrointes-
tinal infections could not be shown. Only a few cases were 
found within 3 months, contributing to imprecise estimates 
of SIRs. 
Within 1 year of acute bacterial gastrointestinal infec-
tion, case-patients with Yersinia enteritis were at increased 
risk for reactive arthritis (SIR 47.0, 95% CI 21.5–89.2), 
Salmonella infection (SIR 18.2, 95% CI 12.0–26.5), and 
Campylobacter infection (SIR 6.3, 95% CI 3.5–10.4) (Ta-
ble 4). The risk for ulcerative colitis was elevated among 
patients with salmonellosis (SIR 3.2, 95% CI 2.2–4.6) and, 
to a lesser extent, among patients with campylobacteriosis 
(SIR 2.8, 95% CI 2.0–3.8). Of the 29 patients in our sal-
monellosis cohort who had ulcerative colitis, 13 (44%) had 
ﬁ  rst experienced ulcerative colitis during the 10-year peri-
od before the acute infection. Among patients with campy-
lobacteriosis, we found 42 with ulcerative colitis, of whom 
18 (43%) had received a diagnosis of ulcerative colitis in 
the 10-year period before the infection. We did not ﬁ  nd any 
Table 1. Distribution of infectious agents, age and sex for 101,855 study participants, Sweden, 1997−2004
Characteristic Nontyphoid Salmonella spp.  Campylobacter spp.  Shigella spp.  EHEC* Yersinia spp. 
No. participants 
 Female  17,524 27,067 2,145 451 2,390
 Male  17,140 30,358 1,668 369 2,743
Mean age, y (range) 
 Female  37  (0−100) 37 (0−99) 33 (1−89) 25 (0−98) 28 (0−95)
 Male  36  (0−97) 37 (0−98) 33 (0−83) 19 (0−85) 27 (0−94)
*EHEC, enterohemorrhagic Escherichia coli.
Table 2. Most frequent serotypes isolated among study 





S. species, not subtyped 14,643 42
S. Enteritidis 10,580 31
S. Typhimurium 2,607 8
S. Virchow 741 2
S. Hadar 734 2
Other specified serotypes 5,359 15
Total 34,664 100
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increased risk for Crohn’s disease in the same group of pa-
tients. We did not ﬁ  nd any elevated risk for many of the 
rheumatologic diseases included in the present study in any 
of the participants. The distribution of Salmonella serotypes 
among patients with aortic aneurysm, reactive arthritis, and 
ulcerative colitis in our cohort did not differ in any sub-
stantial way from the whole salmonellosis cohort (Table 5), 
although the number of patients was rather small. 
Discussion
Our data conﬁ  rm the elevated risk for complications 
and long-term sequelae after an episode of acute bacterial 
gastroenteritis. We have presented new estimates of the 
absolute and relative risk for well-described complications 
such as HUS after EHEC infection, GBS after an episode 
of Campylobacter enteritis, and reactive arthritis after Yer-
sinia  enteritis. Another complication that we have been 
able to verify is aortic aneurysm after an episode of salmo-
nellosis. Perhaps more unexpected, the risk for ulcerative 
colitis was elevated in the cohort of patients with salmonel-
losis and campylobacteriosis. The distribution of Salmonel-
la serovars was the same among patients with and without 
complications. The ﬁ  nding of no major difference in the 
distribution of Salmonella serovars between the group of 
patients with and without complications indicates that fac-
tors other than Salmonella serovar alone determine the risk 
for complications. 
Compared with other studies, our new estimate of the 
risk for HUS after EHEC infection is lower than previ-
ously reported (10,11). An explanation of our lower esti-
mates could be that we used only International Classiﬁ  ca-
tion of Diseases (ICD) codes speciﬁ  c for HUS. Several 
of these cases may in fact be classiﬁ  ed under nonspeciﬁ  c 
ICD codes that also include a large proportion of cases 
unrelated to HUS. However, had we included them in the 
analysis, any association with the infections would have 
Table 3. Complications associated with gastroenteritis, 3 months postinfection, among 101,855 patients with bacterial gastrointestinal
infection, Sweden, 1997−2004*
Disease Infecting organism  Obs Exp SIR 95% CI 
Respiratory system 
Nontyphoid Salmonella spp.  24 13.5 1.8 1.1–2.6   Bacterial pneumonia, pneumonitis 
due to food and vomit  Campylobacter spp.  17 21.4 0.8 0.5–1.3
EHEC 1 0.3 3.1 0.1–17.2
Shigella spp.  1 1.1 0.9 0.02–5.2
Yersinia spp.  4 2.3 1.8 0.5–4.5
Blood
 Hemolytic-uremic  syndrome  Nontyphoid  Salmonella spp.  1 <0.05 55.5 1.4–309.1
Campylobacter spp.  2 <0.05 81.0 9.8–292.7
EHEC 13 <0.05 18,333.4 9,761.8–31,350.6 
Circulatory system 
 Aortic  aneurysm  Nontyphoid  Salmonella spp.  10 1.6 6.4 3.1–11.8
Campylobacter spp.  5 2.4 2.06 0.7–4.8
Yersinia spp.  1 0.2 5.2 0.1–28.9
 Endocarditis  Nontyphoid  Salmonella spp.  2 0.4 5.7 0.7–20.5
Digestive system 
 Peritonitis    Nontyphoid  Salmonella spp.  1 0.6 1.9 0.05–10.1
Campylobacter spp.  2 0.9 2.3 0.4–8.4
Nontyphoid Salmonella spp.  1 0.1 9.7 0.3–54.0  Perforation  of  intestine 
(nontraumatic)  Campylobacter spp.  2 0.2 12.39 1.5–44.7
EHEC 1 <0.05 655.3 16.6–3,651.0
  Idiopathic acute pancreatitis  Nontyphoid Salmonella spp.  6 2.6 2.3 0.9–5.1
Campylobacter spp.  7 4.1 1.7 0.68–3.5
 Hepatic  failure  Nontyphoid  Salmonella spp.  1 0.3 4.0 0.1–22.2
Infectious diseases 
 Septicemia  Nontyphoid  Salmonella spp.  10 2.6 3.9 1.8–7.1
Campylobacter spp.  14 4.1 3.4 1.9–5.7
Shigella spp.  1 0.2 5.1 0.1–28.2
Nervous system 
 Guillain-Barré  syndrome  Campylobacter spp.  13 0.2 66.6 35.5–114.0
Musculoskeletal system 
 Pyogenic  arthritis  Nontyphoid  Salmonella spp.  4 0.8 5.2 1.4–13.4
Yersinia spp.  1 0.1 10.1 0.3–56.2
 Osteomyelitis  Nontyphoid  Salmonella spp.  3 0.6 5.4 1.1–15.7
*Obs, observed number of cases; Exp, expected number of cases; SIR, standardized incidence ratio; CI, confidence interval; EHEC, enterohemorrhagic 
Escherichia coli.
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lobacter are in line with a study in England that showed 
a risk of <2/10,000 that GBS will develop in a patient 
with campylobacteriosis (12). These results are also in 
line with a previous study in Sweden (13). All estimates 
of complications in this study are based on discharge data 
from the Hospital Discharge Register; this means that mi-
nor complications that either were not presented to any 
doctor or were handled only by general practitioners were 
not available for this analysis. At the population level, re-
active rheumatologic symptoms associated with infection 
are typically mild and transient (14). This is probably the 
reason why our estimate of reactive arthritis after Yersin-
ia infection is quite low, although similar low risks have 
been reported elsewhere (15).
In patients with atherosclerotic disease, or in those 
with preexisting aneurysms, transient bacteremia with non-
typhoidal Salmonella infection can result in vascular infec-
tions (16–18). Most of these aneurysms described previ-
ously have been localized in the subrenal segment of the 
Table 4. Complications associated with gastroenteritis, 1 year postinfection, among 101,855 patients with bacterial gastrointestinal
infection, Sweden, 1997−2004*
Disease Infecting organism Obs Exp SIR 95% CI
Digestive system 
 Crohn’s  disease Campylobacter spp. 27 17.1 1.6 1.0–2.3
Salmonella spp. 14 10.3 1.4 0.8–2.3
Shigella spp. 1 1.1 0.9 0.02–5.2
Yersinia spp. 2 1.1 1.8 0.2–6.4
 Ulcerative  colitis Campylobacter spp. 42 14.8 2.8 2.0–3.8
EHEC 1 0.1 6.8 0.2–37.7
Salmonella spp. 29 9 3.2 2.2–4.6
Yersinia spp. 3 1 2.9 0.6–8.5
Campylobacter spp. 37 14.9 2.5 1.8–3.4  Other  specified/unspecified  noninfective 
gastroenteritis and colitis Salmonella spp. 30 9.2 3.3 2.2–4.6
Yersinia spp. 10 1.3 7.6 3.7–14.0
  Irritable bowel syndrome Campylobacter spp. 15 5 3.0 1.7–5.0
Salmonella spp. 5 3 1.7 0.5–3.9
Yersinia spp. 3 0.4 7.8 1.6–22.9
 Intestinal  malabsorption Salmonella spp. 1 0.6 1.7 0.04–9.3
Yersinia spp. 1 0.1 7.9 0.2–43.7
Musculoskeletal system 
Campylobacter spp. 15 2.4 6.3 3.5–10.4   Postdysenteric arthropathy, Reiter disease, 
other reactive arthropathies Salmonella spp. 27 1.5 18.2 12.0–26.5
Shigella spp. 2 0.1 13.4 1.6–48.4
Yersinia spp. 9 0.2 47.0 21.5–89.2
 Rheumatoid  arthritis Campylobacter spp. 22 22.5 1.0 0.6–1.5
EHEC 1 0.2 5.8 0.2–32.1
Salmonella spp. 9 14.7 0.6 0.3–1.2
Shigella spp. 1 1.2 0.8 0.02–4.7
Yersinia spp. 3 1.5 2.0 0.4–5.7
 Other  arthritis Campylobacter spp. 8 3.8 2.1 0.9–4.2
Salmonella spp. 4 2.5 1.6 0.4–4.1
Shigella spp. 1 0.2 4.3 0.1–24.1
Yersinia spp. 1 0.4 2.4 0.06–13.4
Campylobacter spp. 10 3.3 3.1 1.5–5.6
EHEC 0 <0.05 32.8 0.8–183.0
 Other  necrotizing  vasculopathies 
(Goodpasture syndrome, TTP, Wegener 
granulomatosis, giant cell arteritis) Salmonella spp. 1 2.1 0.5 0.01–2.7
  Systemic lupus erythematosus Campylobacter spp. 5 3.4 1.5 0.5–3.4
Salmonella spp. 2 2.1 1.0 0.1–3.5
 Systemic  sclerosis Campylobacter spp. 2 1.7 1.2 0.2–4.4
Salmonella spp. 3 1.1 2.8 0.6–8.1
Campylobacter spp. 12 5 2.4 1.2–4.2
Salmonella spp. 4 3.1 1.3 0.4–3.3
  Other systemic involvement of connective 
tissue (Sjögren syndrome, mixed connective 
tissue disease, polymyalgia rheumatica) Shigella spp. 1 0.2 4.2 0.1–23.3
 Ankylosing  spondylitis Campylobacter spp. 2 1.1 1.8 0.2–6.4
Salmonella spp. 1 0.7 1.5 0.04–8.1
*Obs, observed number of cases; Exp, expected number of cases; SIR, standardized incidence ratio; CI, confidence interval; EHEC, enterohemorrhagic 
Escherichia coli.; TTP, thrombotic thrombocytopenic purpura. 
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abdominal aorta (17). Salmonella spp. in these patients can 
invade the arterial intima and cause a localized endothelial 
infection that results in an aneurysm or the enlargement of 
a previously existing aneurysm. This may explain the asso-
ciation between Salmonella infection and aortic aneurysm 
in this study. 
Our ﬁ  ndings of an elevated risk for ulcerative colitis in 
the cohort of patients with salmonellosis and campylobac-
teriosis need further study. In another large cohort study, 
an association between acute gastroenteritis and inﬂ  am-
matory bowel disease was identiﬁ  ed (n = 43,013), where 
the incidence rate for ulcerative colitis was 40 per 100,000 
person-years, a doubling of the risk for those unexposed 
to infection (19). We do not know why an episode of in-
fectious gastroenteritis could contribute to the initiation 
or exacerbation of ulcerative colitis. Seasonal variation in 
the onset of ulcerative colitis, and reports that excessive 
childhood infections are associated with higher risk for ul-
cerative colitis, may support the hypothesis that infections 
could be triggers of disease (20). From this study, we can-
not say whether there is a causal relationship between Sal-
monella and Campylobacter infections and relapse of dis-
ease in patients with known ulcerative colitis, or whether 
the infection could trigger ulcerative colitis in susceptible 
persons. We cannot entirely rule out that the ﬁ  ndings are 
an artifact, resulting from an increased number of medical 
examinations and stool cultures in a group of patients with 
diarrhea because of a known or unknown inﬂ  ammatory 
bowel disease. More study is needed to conﬁ  rm or refute 
our ﬁ  ndings. 
Because irritable bowel syndrome is diagnosed and 
treated at hospital in only a minority of patients, our esti-
mates are probably too low. Many studies have not used a 
control group but reported only the numbers and percentag-
es of patients who had irritable bowel syndrome after gas-
troenteritis (21); 1 study with controls estimated a relative 
risk of 11.9 (CI 6.7–21) after 1 year of follow-up (22).
Our study has some limitations. Perhaps the most seri-
ous one is the selection bias of patients entering the gas-
troenteritis cohort. Only a small fraction of all patients 
with Salmonella infection, for example, seek medical care, 
have a stool sample taken, and are eventually reported to 
national surveillance (23). This could have an effect on the 
results, especially if we are collecting data on those with 
the most severe disease; disease severity itself affects com-
plications and sequelae. Another limitation is the lack of 
information on confounding factors among study partici-
pants, especially coexisting illnesses such as malignant dis-
ease or immunodeﬁ  ciencies of any cause. Such coexisting 
illnesses could perhaps increase to some extent the risk for 
complications (6), but our results on the effect of disease 
from gastrointestinal infections would not have changed. 
Although the quality of the Swedish Hospital Discharge 
Register is quite good, there is always a general problem of 
reliability in registry-based epidemiologic research. 
In conclusion, we studied the risk for complications 3 
months and 1 year after acute bacterial gastroenteritis and 
found disease manifestations from several organ systems 
that required hospitalization of patients. These ﬁ  ndings are 
a reminder of, and could be an argument for, the usefulness 
of existing control programs targeted to control bacterial 
enteric disease. 
This study was approved by the Regional Ethical Commit-
tee, Karolinska Institute, Stockholm, Sweden.  
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Hospital and a PhD student at Karolinska Institute, Department 
of Medical Epidemiology and Biostatistics, Sweden. His research 
interests are in infectious disease epidemiology, registry-based re-
search, and long-term prognosis of infectious diseases. 
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